PF-Atlas › Clinical Trials › NCT04072315

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

PLN-74809 · Phase 2

Registry ID
NCT04072315
Phase
Phase 2
Status
Completed
Drug / intervention
PLN-74809
Sponsor
Pliant Therapeutics, Inc.
Start
2020-02-13
Enrollment
9
Locations
1

About this trial

A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.

View NCT04072315 on ClinicalTrials.gov →

Explore related

PLN-74809 — Treatment profileAll PLN-74809 trialsAll IPF trials

Related trials

PLN-74809 — INTEGRIS-IPFPLN-74809 — NCT04396756PLN-74809 — NCT06097260
Medical disclaimer. This page summarizes public trial data for NCT04072315 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.